Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

BTTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 51.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Better Therapeutics Insider Trading History Chart

Better Therapeutics Share Price & Price History

^$0.00

+0.30 (1.20%)

As of 12/20/2024 03:47 PM ET

Days: 30 | 90 | 365

Collect $7k per month from Tesla’s SECRET dividend

From Investors Alley | Ad

Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…

Click here to discover the new #1 way to invest in Tesla

Better Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/27/2023	Andrew J. Armanino	Director	Buy	274,010	$0.73	$200,027.30	728,368
7/27/2023	David P Perry	Chairman	Buy	1,233,045	$0.73	$900,122.85	13,030,393
7/27/2023	Frank Karbe	CEO	Buy	137,005	$0.73	$100,013.65	429,429
7/27/2023	Mark A Berman	Insider	Buy	54,802	$0.73	$40,005.46	388,191
5/16/2023	Elder Granger	Director	Buy	600	$0.87	$522.00	1,600
4/10/2023	Frank Karbe	Insider	Buy	242,424	$0.82	$198,787.68	292,424
4/10/2023	Geoffrey M Parker	Director	Buy	303,030	$0.82	$248,484.60	343,030
9/15/2022	Frank Karbe	Insider	Buy	50,000	$2.09	$104,500.00	50,000
9/12/2022	Mark Heinen	Insider	Buy	23,868	$1.94	$46,303.92	43,868
6/24/2022	Mark Heinen	Insider	Buy	2,281	$1.75	$3,991.75	2,281
6/13/2022	Geoffrey M Parker	Director	Buy	25,000	$1.45	$36,250.00	40,000
6/10/2022	Mark Heinen	Insider	Buy	5,000	$1.56	$7,800.00	20,000
3/31/2022	Kevin J. Appelbaum	CEO	Buy	2,500	$1.97	$4,925.00	6,250
3/31/2022	Mark Heinen	Insider	Buy	5,000	$1.98	$9,900.00	15,000
3/29/2022	Andrew J. Armanino	Director	Buy	40,000	$2.14	$85,600.00
12/21/2021	Risa J. Lavizzo-Mourey	Director	Buy	10,000	$4.60	$46,000.00

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

SEC Filings (Institutional Ownership Changes) for Better Therapeutics (NASDAQ:BTTX)

34.00% of Better Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Better Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/12/2024	MMCAP International Inc. SPC	356,270	$65K	0.0%	-77.5%	0.715%
11/14/2023	MMCAP International Inc. SPC	1,583,079	$0.58M	0.2%	N/A	3.340%
5/15/2023	Farallon Capital Management LLC	699,042	$0.51M	0.0%	-14.1%	2.931%
5/10/2022	Sectoral Asset Management Inc.	878,531	$1.74M	0.3%	-9.8%	3.721%
5/4/2022	Victory Capital Management Inc.	272,720	$0.54M	0.0%	N/A	1.155%

Data available starting January 2016

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.

Today's Range

Now: $0.00

$0.00

50 Day Range

MA: N/A

52 Week Range

Now: $0.00

$0.00

$0.27

Volume

24,101 shs

Average Volume

2,290,967 shs

Market Capitalization

$4,986.20

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Who are the company insiders with the largest holdings of Better Therapeutics?: Better Therapeutics' top insider shareholders include:
David P Perry (Chairman)
Andrew J Armanino (Director)
Frank Karbe (CEO)
Mark A Berman (Insider)
Geoffrey M Parker (Director)
Frank Karbe (Insider)
Elder Granger (Director)
Learn More about top insider investors at Better Therapeutics.

The #1 Coin for November 2024

From Crypto 101 Media | Ad